Pharmacists in Manville, NJ Accepting Medicare

13 Pharmacists found. Showing 1 - 13

Miss Karen Ann Lewandowski, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 120 N Main St, Manville, NJ 08835 Phone: 908-685-8858

Tien Ngoc Tran Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 27 S Main St, Manville, NJ 08835 Phone: 908-566-1221

Mr. Kevin O'connor, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 27 S Main St, Manville, NJ 08835 Phone: 908-566-1221

Mr. Scott Charles Mylroie, RPH, CCP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 N Main St, Manville, NJ 08835 Phone: 908-575-8903    Fax: 908-575-8903

Dr. Sophia Kim, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 321 S Main St, Manville, NJ 08835 Phone: 908-725-8050

Bhavin Shah Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 321 S Main St, Manville, NJ 08835 Phone: 908-725-8050    Fax: 908-575-0879

Aisha S. Bhatti, PHARMD,RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 321 S Main St, Manville, NJ 08835 Phone: 908-725-8050

Mr. Kiran Parvatrao, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 931 Kennedy Blvd, Manville, NJ 08835 Phone: 908-722-7002    Fax: 732-667-7017

Mr. Gaurab Sanyal, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 N Main St, Manville, NJ 08835 Phone: 908-575-8928    Fax: 908-575-8903

Payal S Shetty, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 321 S Main St, Manville, NJ 08835 Phone: 908-725-8050    Fax: 908-575-0879

Anthony Lawrence, RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 27 S Main St, Walgreens, Manville, NJ 08835 Phone: 908-566-1221    Fax: 908-566-1252

Sima Thakkar Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 N Main St, Manville, NJ 08835 Phone: 908-575-8928

Suzy Samir Mikhail Morcos Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 321 S Main St, Manville, NJ 08835 Phone: 908-725-8050

News Archive

Algeta partners with Bayer for development and commercialization of Alpharadin drug

Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development

False positive cancer screening tests result not only in anxiety but also additional economic costs

Cancer screening tests can frequently produce false positive outcomes that may result not only in anxiety but also additional economic costs as well, according to research conducted by scientists at the Henry Ford Health System, Detroit, Mich., and published in the December issue of Cancer Epidemiology, Biomarkers & Prevention

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer.

Leconotide, an investigative calcium channel blocker, shows potential as pain treatment

Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

New therapeutic options for newly diagnosed multiple myeloma patients

Mayo Clinic researchers presented results of a phase II trial of myeloma induction therapy - a first step therapy designed to reduce cancer cells numbers - with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.

Read more Medical News

› Verified 4 days ago